Home / Health / FDA Warns Telehealth Firms Over Fake Weight Loss Drugs
FDA Warns Telehealth Firms Over Fake Weight Loss Drugs
17 Jun
Summary
- FDA sent 25 warning letters to telehealth companies.
- Companies made false claims about compounded weight loss drugs.
- Compounded drugs lack proven safety and consistent quality.
As of June 17, 2026, the U.S. Food and Drug Administration (FDA) has issued 25 warning letters to various telehealth companies. These companies were found to be marketing false and misleading claims about compounded versions of widely used weight loss and diabetes medications.
The warning letters, posted on the regulator's website earlier this month, target firms such as Medica Weight Loss and Ready Med. These companies allegedly claimed their compounded drugs, such as tirzepatide and semaglutide, were sourced from FDA-approved pharmacies or contained clinically studied ingredients.
The FDA stated that these representations are false or misleading. Some companies implied their compounded products were identical to approved GLP-1 drugs or showed their products in a manner suggesting compounding. These customized medicines, made by combining or altering ingredients, are not approved by the FDA.
Acting Director Michael Davis of the FDA's Center for Drug Evaluation and Research stated, "Patients deserve to know what they're getting -- compounded GLP-1 products have not been proven safe, effective, or of consistent quality like FDA-approved drugs." The agency plans to continue holding accountable companies making such claims.
